Company intelligence / Profile preview
Luoxin Pharmaceutical Group Stock Co., Ltd.
Linyi, Shandong, China
- Ownership
- Private
- Employees
- ~3388
- Development stage
- Commercial
01
Overview
Luoxin Pharmaceutical has a broad commercial portfolio with over 300 marketed products including more than 48 national new drugs. Its pipeline includes innovative drugs such as an oral SERD for ER+ breast cancer in Phase I trials and a potassium competitive acid blocker that met its primary endpoint in Phase III for erosive esophagitis. The company also holds exclusive China rights to Budesolv® budesonide nasal spray from Marinomed Biotech AG which reached Phase III status. It co-develops third-generation EGFR inhibitors with Yuhan Corporation targeting NSCLC patients with resistance mutations.
- Therapeutic areas
- PulmonologyOncologyGastroenterology
- Modalities
- Small molecules (e.g. budesonide nasal spray, potassium competitive acid blocker)oral SERDs (selective estrogen receptor degraders)targeted therapies (EGFR inhibitors)
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Marinomed Biotech AG – licensing of Budesolv® budesonide nasal spray for China regionJW Holdings – exclusive development agreement on parenteral nutrition productAurobindo Pharma – joint venture on respiratory products/R&D/manufacturing for global supplyYuhan Corporation – co-development/license of third-generation EGFR inhibitor YH25448 for NSCLC in China/Hong Kong/Macau regions
Beyond the preview
Go deeper on Luoxin Pharmaceutical Group Stock Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luoxin Pharmaceutical Group Stock Co., Ltd..